N-acetylcysteine and contrast-induced nephropathy [5]

New England Journal of Medicine

Volumn 355, Issue 14, 2006, Pages 1497-1498

  Aguiar Souto, Pablo ^a   Valero González, Sara ^a   Oteo Domínguez, Juan F ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATININE;

ANGIOPLASTY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; HUMAN; INCIDENCE; KIDNEY DISEASE; LETTER; PRIORITY JOURNAL;

ACETYLCYSTEINE; CONTRAST MEDIA; CREATININE; HUMANS; KIDNEY DISEASES;

EID: 33749440306     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc061983     Document Type: Letter

References (5)

1. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-82.
2. Baker CSR, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003;41:2114-8.
3. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004;25:206-11.
4. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
5. Barrett BJ, Parfrey PS. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354:379-86.